

101250

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08237 A2

- (51) International Patent Classification⁷: C07H
 (21) International Application Number: PCT/US01/23079
 (22) International Filing Date: 20 July 2001 (20.07.2001)
 (25) Filing Language: English
 (26) Publication Language: English
 (30) Priority Data:
 60/220,096 21 July 2000 (21.07.2000) US
 09/910,697 20 July 2001 (20.07.2001) US
 (71) Applicant and
 (72) Inventor: LYLES, Mark, B. [US/US]; 9127 Cap Mountain Drive, San Antonio, TX 78255 (US).
 (74) Agents: BUNTEL, Christopher, J. et al.; Baker Botts L.L.P., 910 Louisiana, Houston, TX 77002 (US).
 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
 (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
 Published:
 — without international search report and to be republished upon receipt of that report
 For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/08237 A2

(54) Title: MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES

(57) Abstract: Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids. Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthines, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts.

MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES

FIELD OF THE INVENTION

The invention relates to silica surfaces useful for binding nucleic acids, and
5 formulations to improve the binding of nucleic acids to surfaces. In particular, high
purity silica (silicon dioxide) surfaces are disclosed. Additionally, nucleic acid
formulations containing materials which mask the electrostatic interactions between
nucleic acids and surfaces are disclosed.

BACKGROUND OF THE INVENTION

10 The binding of nucleic acids, especially DNA, to surfaces has been reported
many times in the scientific literature. Binding may be accomplished either through
non-specific electrostatic or hydrophobic means, or through formation of covalent
bonds to the terminus of the nucleic acid.

Covalent bonding of nucleic acids to surfaces is generally preferred, as it
15 specifically orients the nucleic acids in a given manner. The bonded nucleic acids may
be used for hybridization experiments when contacted with other nucleic acids in
solution.

Traditionally, glass has been used as the substrate for binding nucleic acids.
The glass is heated in order to produce slides or beads. During heating, impurities tend
20 to migrate towards the surface of the material, reducing the surface area available for
binding nucleic acids.

Electrostatic interactions between the nucleic acids and the surface result in a
fraction of the nucleic acids becoming nonspecifically bound to the surface. This may
result in nucleic acids "laying down" or orienting themselves parallel to the surface,
25 rather than being perpendicular to the surface. This orientation reduces or eliminates
the ability of the bound nucleic acid to interact with other nucleic acids in solution, and
additionally may result in the blockage of other covalent bonding sites on the surface.

There exists a need for improved materials for the preparation of nucleic acids bound to surfaces, and methods to improve the specific covalent bonding of nucleic acids to surfaces.

SUMMARY OF THE INVENTION

5 Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids.

Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be
10 minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthenes, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts. Other materials such
15 as amines may be used if the pH of the formulation is such that the material is positively charged.

DETAILED DESCRIPTION OF THE INVENTION

The prior art materials and formulations have been plagued with two general problems; a) low loading potential of the surfaces; and b) nonspecific binding of
20 nucleic acids to the surface.

A first embodiment of the invention relates to the use of substantially pure silica (silicon dioxide) in surfaces. As there are essentially no impurities in the material, essentially the entire surface of the material is available for binding nucleic acids. Preferably the material is at least about 70% pure, about 80% pure, about 90% pure,
25 about 95% pure, about 96% pure, about 97% pure, about 98% pure, about 99% pure, about 99.5% pure, about 99.9% pure, and ideally about 100% pure by weight. The resulting surface will exhibit higher loading potential for nucleic acids than does conventional glass surfaces. At a microscopic level, the silica surface preferably has a three dimensional structure, and is not planar. An example of a three dimensional
30 structure is an array of silica fibers.

The surface may be generally be any shape, and preferably is macroscopically planar (e.g. a chip or disk) or three dimensional (e.g. a sphere or bead).

The surface properties of the materials may be modified by chemical reactions. Examples include modifying the hydrophobicity or hydrophilicity of the materials.

5 The surface may be constructed entirely of the substantially pure silica, or may comprise a layer of substantially pure silica mounted on top of a flat surface such as glass or metal. The substantially pure silica may be adhered to the flat surface by an adhesive, applied using a solvent, or cast directly onto the flat surface.

10 Substantially pure silica may be purchased from a commercial supplier, may be prepared *de novo*, or may be prepared by purifying silica containing impurities. Methods for treating and purifying silica fibers are taught in U.S. Patent No. 5,951,295. These methods may be used to purify commercial or prepared silica materials so as to render them substantially pure. The purified silica materials may then be used to prepare the surfaces described herein.

15 The surface may be used to bind generally any nucleic acids, preferably DNA or RNA, and more preferably DNA. The nucleic acids may be bound to the surface using any acceptable chemical method. Chemical reactions for the covalent bonding of nucleic acids to surfaces containing silica are known in the art.

20 An additional embodiment of the invention relates to formulations suitable for the binding of nucleic acids to surfaces. Formulations are prepared comprising nucleic acids and a charged material. The charged material preferably is partially or fully cationic. The charged material may generally be any partially or fully positively charged material suitable for interaction with the phosphate groups of nucleic acids. Examples of suitable charged materials include xanthines, hexoses, purines, arginine,
25 lysine, polyarginine, polylysine, and quaternary ammonium salts. The xanthine may generally be any xanthine, and preferably is xanthine, 1,3,7-trimethylxanthine (caffeine), 1,3,9-trimethylxanthine, 1,3-diethyl-7-methylxanthine, 1,3-diethyl-8-phenylxanthine, 1,3-dimethyl-7-(2-hydroxyethyl)xanthine, 1,3-dimethylxanthine-7-acetic acid, 1,3-dipropyl-7-methylxanthine, 1,3-dipropyl-8-*p*-sulfophenylxanthine, 1,7-
30 dimethylxanthine, 1,7-dimethylxanthine (paraxanthine), 1,9-dimethylxanthine, 1-allyl-3,7-dimethyl-8-phenylxanthine, 1-allyl-3,7-dimethyl-8-*p*-sulfophenylxanthine, 1-butyl-4,5-dihydro-3-ethyl-8-hydroxyxanthine, 1-ethyl-3-isobutylxanthine, 1-methylxanthine,

2,6-dithiopurine, 2'-deoxyinosine, 3,7-dimethyl-1-propargylxanthine, 3,7-dimethylxanthine, 3,8-dimethyl-2-thioxanthine, 3,9-dimethylxanthine, 3-allyl-1-ethyl-8-hydroxyxanthine, 3-cyclopropyl-1-ethyl-8-hydroxyxanthine, 3-ethyl-1-propylxanthine, 3-ethyl-8-hydroxy-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-methyl-1-(5-oxohexyl)-7-propylxanthine, 3-methyl-8-phenyl-2-thiohypoxanthine, 3-methylxanthine, 3-propylxanthine, 6-thiohypoxanthine, 6-thioxanthine, 7-methylxanthine, 8-(3-carboxypropyl)-1,3-dimethylxanthine, 8-azaxanthine monohydrate, 8-bromo-1,3-diethylxanthine, 8-cyclopentyl-1,3-dimethylxanthine, 8-cyclopentyl-1,3-dipropylxanthine, 8-methoxymethyl-3-isobutyl-1-methylxanthine, 8-methylxanthine, 9-methylxanthine, azaserine-hypoxanthine, hypoxanthine, hypoxanthine 9-beta-d-arabinofuranoside, hypoxanthine 9-d-ribofuranoside (inosine), nicotinamide hypoxanthine dinucleotide phosphate, nicotinamide hypoxanthine dinucleotide phosphate disodium salt, nicotinamide hypoxanthine dinucleotide sodium salt, selenohypoxanthine, or xanthosine. The hexose may generally be any hexose, and preferably is alose, altrose, fructose, galactose, glucose, mannose, sorbose, tagatose, or talose, and more preferably is glucose. The hexose may be the D- or L- isomer. The purine may generally be any purine, and preferably is purine, 6-purinecarbonitrile, 6-purinethiol, or 6-purinethiol riboside. The quaternary ammonium salt may generally be any quaternary ammonium salt, and preferably is benzyltriethyl ammonium chloride (BTEAC), benzyltrimethyl ammonium chloride (BTMAC), benzyltributyl ammonium chloride (BTBAC), tetrabutyl ammonium bromide (TBAB), tetramethyl ammonium chloride (TMAC), tetrabutyl ammonium hydrogensulfate (TBAHS), trioctylmethyl ammonium chloride (TOMAC), N-lauryl pyridinium chloride (PYLC), or N-alkyl-(pyridinium / picolinium) chloride.

The charged material may serve multiple roles in the formulation, e.g. a surfactant may also interact with the phosphate groups of nucleic acids. The charged material may be affected by the pH of the formulation, e.g. amines may be protonated at low pH and deprotonated at high pH. The formulation is preferably a homogeneous mixture, and more preferably is a homogeneous aqueous mixture.

The charged material "masks" the charged phosphate groups of the nucleic acids, reducing or eliminating the potential for nonspecific binding of the nucleic acids

to the silica surface by electrostatic attraction. As a result, the amount of nucleic acids nonspecifically binding to the surface is reduced or eliminated.

An additional embodiment of the invention is a method for the binding of nucleic acids to a surface. The method generally involves contacting the above
5 described formulation with a surface containing silica. A particularly preferred embodiment involves contacting the above described formulation with a surface consisting essentially of silica. Any acceptable chemical methodology may be used to covalently bond the nucleic acids to the surface in the presence of the formulation.

The charged material in the formulation reduces nonspecific binding of the
10 nucleic acids to the surface relative to nonspecific binding of nucleic acids to the surface in the absence of the charged material. Preferably, the method substantially eliminates nonspecific binding of the nucleic acids to the surface, and more preferably eliminates nonspecific binding of the nucleic acids to the surface. After the contacting step, the charged material may be removed, e.g. by a washing step.

15 All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may
20 be applied to the compositions and/or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar
25 substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.

What is claimed is:

1. A material consisting essentially of:
silica; and
nucleic acids covalently bonded to the silica.
2. The material of claim 1, wherein the nucleic acids are DNA.
3. The material of claim 1, wherein the material is a flat surface.
4. The material of claim 1, wherein the material is a bead.
5. The material of claim 1, wherein the material is an array of fibers.
6. The material of claim 1, wherein the silica is at least about 80% pure silicon dioxide.
7. The material of claim 1, wherein the silica is at least about 90% pure silicon dioxide.
8. The material of claim 1, wherein the silica is at least about 95% pure silicon dioxide.
9. The material of claim 1, wherein the silica is pure silicon dioxide.
10. A material consisting of:
silica; and
nucleic acids covalently bonded to the silica.
11. The material of claim 10, wherein the nucleic acids are DNA.
12. The material of claim 10, wherein the material is a flat surface.
13. The material of claim 10, wherein the material is a bead.
14. The material of claim 10, wherein the material is an array of fibers.
15. The material of claim 10, wherein the silica is at least about 80% pure silicon dioxide.
16. The material of claim 10, wherein the silica is at least about 90% pure silicon dioxide.
17. The material of claim 10, wherein the silica is at least about 95% pure silicon dioxide.
18. The material of claim 10, wherein the silica is pure silicon dioxide.
19. A method for binding nucleic acids to a surface, the method comprising:
providing a mixture comprising nucleic acids and a charged material; and

contacting the mixture and a surface to produce a bound material, wherein the bound material comprises nucleic acids covalently bonded to the surface.

20. The method of claim 19, wherein the charged material is a cationic material or a partially cationic material.
21. The method of claim 19, wherein the charged material is a xanthine, a hexose, a purine, arginine, lysine, polyarginine, polylysine, or a quaternary ammonium salt.
22. The method of claim 21, wherein the xanthine is xanthine, 1,3,7-trimethylxanthine (caffeine), 1,3,9-trimethylxanthine, 1,3-diethyl-7-methylxanthine, 1,3-diethyl-8-phenylxanthine, 1,3-dimethyl-7-(2-hydroxyethyl)xanthine, 1,3-dimethylxanthine-7-acetic acid, 1,3-dipropyl-7-methylxanthine, 1,3-dipropyl-8-*p*-sulfophenylxanthine, 1,7-dimethylxanthine, 1,7-dimethylxanthine (paraxanthine), 1,9-dimethylxanthine, 1-allyl-3,7-dimethyl-8-phenylxanthine, 1-allyl-3,7-dimethyl-8-*p*-sulfophenylxanthine, 1-butyl-4,5-dihydro-3-ethyl-8-hydroxyxanthine, 1-ethyl-3-isobutylxanthine, 1-methylxanthine, 2,6-dithiopurine, 2'-deoxyinosine, 3,7-dimethyl-1-propargylxanthine, 3,7-dimethylxanthine, 3,8-dimethyl-2-thioxanthine, 3,9-dimethylxanthine, 3-allyl-1-ethyl-8-hydroxyxanthine, 3-cyclopropyl-1-ethyl-8-hydroxyxanthine, 3-ethyl-1-propylxanthine, 3-ethyl-8-hydroxy-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 3-methyl-1-(5-oxohexyl)-7-propylxanthine, 3-methyl-8-phenyl-2-thiohypoxanthine, 3-methylxanthine, 3-propylxanthine, 6-thiohypoxanthine, 6-thioxanthine, 7-methylxanthine, 8-(3-carboxypropyl)-1,3-dimethylxanthine, 8-azaxanthine monohydrate, 8-bromo-1,3-diethylxanthine, 8-cyclopentyl-1,3-dimethylxanthine, 8-cyclopentyl-1,3-dipropylxanthine, 8-methoxymethyl-3-isobutyl-1-methylxanthine, 8-methylxanthine, 9-methylxanthine, azaserine-hypoxanthine, hypoxanthine, hypoxanthine 9-beta-d-arabinofuranoside, hypoxanthine 9-d-ribofuranoside (inosine), nicotinamide hypoxanthine dinucleotide phosphate, nicotinamide hypoxanthine dinucleotide phosphate disodium salt, nicotinamide hypoxanthine dinucleotide sodium salt, selenohypoxanthine, or xanthosine.

23. The method of claim 21, wherein the hexose is alose, altrose, fructose, galactose, glucose, mannose, sorbose, tagatose, or talose.
24. The method of claim 21, wherein the purine is purine, 6-purinecarbonitrile, 6-purinethiol, or 6-purinethiol riboside.
25. The method of claim 21, wherein the quaternary ammonium salt is benzyltriethyl ammonium chloride (BTEAC), benzyltrimethyl ammonium chloride (BTMAC), benzyltributyl ammonium chloride (BTBAC), tetrabutyl ammonium bromide (TBAB), tetramethyl ammonium chloride (TMAC), tetrabutyl ammonium hydrogensulfate (TBAHS), trioctylmethyl ammonium chloride (TOMAC), N-lauryl pyridinium chloride (PYLC), or N-alkyl-(pyridinium / picolinium) chloride.
26. The method of claim 19, wherein the surface consists essentially of silica.
27. The method of claim 19, wherein the surface consists of silica.
28. The method of claim 19, further comprising removing the charged material after the contacting step.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/008237 A3

(51) International Patent Classification⁷: C07H 21/00,
C07B 61/00

(21) International Application Number: PCT/US01/23079

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/220,096 21 July 2000 (21.07.2000) US
09/910,697 20 July 2001 (20.07.2001) US

(71) Applicant and

(72) Inventor: LYLES, Mark, B. [US/US]; 9127 Cap Mountain Drive, San Antonio, TX 78255 (US).

(74) Agents: BUNTEL, Christopher, J. et al.; Baker Botts L.L.P., 910 Louisiana, Houston, TX 77002 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
7 November 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES

(57) Abstract: Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids. Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthines, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts.



WO 02/008237 A3

INTERNATIONAL SEARCH REPORT

Inten Application No
PCT/US 01/23079

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07H21/00 C07B61/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07H C07B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'DONNELL-MALONEY M J ET AL: "Microfabrication and array technologies for DNA sequencing and diagnostics" GENETIC ANALYSIS: BIOMOLECULAR ENGINEERING, ELSEVIER SCIENCE PUBLISHING, US, vol. 13, no. 6, 1 December 1996 (1996-12-01), pages 151-157, XP004017264 ISSN: 1050-3862 page 151 -page 152 --- -/--	1-3, 9-12,18
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search 28 June 2002		Date of mailing of the international search report 12/07/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Held, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23079

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLOAREC J P ET AL: "Functionalization of Si/SiO ₂ substrates with homooligonucleotides for a DNA biosensor" SENSORS AND ACTUATORS B, ELSEVIER SEQUOIA S.A., LAUSANNE, CH, vol. 58, no. 1-3, 21 September 1999 (1999-09-21), pages 394-398, XP004253038 ISSN: 0925-4005 page 394 -page 395, left-hand column, paragraph 1	1-4, 9-13,18
X	US 5 808 041 A (BURKIEWICZ ADAM ET AL) 15 September 1998 (1998-09-15) column 3, line 19 -column 4, line 42 claims 1,4	1,2,4, 10,11, 13,19, 20,26-28
X	WO 95 34569 A (BENDZKO PETER ;HILLEBRAND TIMO (DE); INVITEK GMBH (DE); PETERS LAR) 21 December 1995 (1995-12-21) claims 1,3	1,2,4, 9-11,13, 19,20, 26-28
X	DATABASE WPI Section Ch, Week 199404 Derwent Publications Ltd., London, GB; Class B04, AN 1994-028621 XP002203983 -& JP 05 333015 A (NEOS KK), 17 December 1993 (1993-12-17) abstract claims	1,2,10, 11, 19-21, 25-27
A	LEONARD M: "New packing materials for protein chromatography" JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 699, no. 1-2, 10 October 1997 (1997-10-10), pages 3-27, XP004094986 ISSN: 1570-0232 figures 1,2 page 7, right-hand column, paragraph 3 -page 8, left-hand column, paragraph 1 page 11 -page 12	1,10,19
A	WO 95 06056 A (UNIV NEW JERSEY MED) 2 March 1995 (1995-03-02) page 5, line 9 - line 23	19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/23079

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5808041	A	15-09-1998	AU 689815 B2	09-04-1998
			AU 8010094 A	22-03-1995
			CA 2170604 A1	09-03-1995
			EP 0723549 A1	31-07-1996
			JP 9505724 T	10-06-1997
			WO 9506652 A1	09-03-1995
			US 5658548 A	19-08-1997
<hr/>				
WO 9534569	A	21-12-1995	DE 4422040 A1	21-12-1995
			DE 4422044 A1	21-12-1995
			DE 4447015 A1	04-07-1996
			AT 184013 T	15-09-1999
			WO 9534569 A1	21-12-1995
			DE 59506735 D1	07-10-1999
			EP 0765335 A1	02-04-1997
			JP 10501246 T	03-02-1998
			US 6037465 A	14-03-2000
<hr/>				
JP 5333015	A	17-12-1993	JP 3206111 B2	04-09-2001
<hr/>				
WO 9506056	A	02-03-1995	AU 7634694 A	21-03-1995
			WO 9506056 A1	02-03-1995
<hr/>				